ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,037.24
-0.16%
US Tech 100
20,599.20
-0.06%
다우존스 지수
44,593.95
-0.42%
Bitcoin
95,231.66
-0.66%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Arbutus Biopharma Corporation (ABUS) 시세

Arbutus Biopharma Corporation

Arbutus Biopharma Corporation (ABUS)

NASDAQ
3.425
-0.035
( -1.01% )
업데이트: 01:36:18
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

주요 통계 및 세부정보

가격
3.425
매수가
3.42
매도가
3.43
거래량
116,216
3.365 일간 변동폭 3.48
1.98 52주 범위 4.725
market_cap
649.009M
전일 종가
3.46
개장가
3.47
최근 거래 시간
25
@
3.4299
마지막 거래 시간
01:41:48
재정 규모
US$ 397,761
VWAP
3.4226
평균 볼륨(3m)
1,041,576
발행 주식
189,491,685
배당수익률
-
주가수익률
-8.82
주당순이익(EPS)
-0.38
매출
18.14M
순이익
-72.85M

Arbutus Biopharma Corporation 정보

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid na... Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.tekmirapharm.com
본부
Burnaby, British Columbia, Can
설립됨
-
Arbutus Biopharma Corporation is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker ABUS. The last closing price for Arbutus Biopharma was US$3.46. Over the last year, Arbutus Biopharma shares have traded in a share price range of US$ 1.98 to US$ 4.725.

Arbutus Biopharma currently has 189,491,685 shares in issue. The market capitalisation of Arbutus Biopharma is US$655.64 million. Arbutus Biopharma has a price to earnings ratio (PE ratio) of -8.82.

ABUS 최신 뉴스

추가 뉴스

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Believes Now Is the Logical Time for Arbutus to Pursue a License and Collaboration Agreement With a Strategic Partner and Explore All Options for HBV Portfolio Urges Arbutus to Commit to No...

4 시간 전
Business Wire

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...

26 11월 2024
GlobeNewswire Inc.

Form 8-K - Current report

16 11월 2024
Edgar (US Regulatory)

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved...

16 11월 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 11월 2024
Edgar (US Regulatory)

Arbutus to Present at Jefferies London Healthcare Conference

WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...

14 11월 2024
GlobeNewswire Inc.

Form S-3 - Registration statement under Securities Act of 1933

07 11월 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 11월 2024
Edgar (US Regulatory)

Form 8-K - Current report

06 11월 2024
Edgar (US Regulatory)

Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024 Multiple-ascending doses of AB-101 in healthy subjects in the...

06 11월 2024
GlobeNewswire Inc.
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.025-0.7246376811593.453.523.3655586863.44874083CS
4-0.435-11.26943005183.863.963.3659423973.60106089CS
12-1.1013-24.33113138774.52634.613.36510415763.9313697CS
260.0651.934523809523.364.7252.91510451273.7611022CS
521.41570.39800995022.014.7251.9810591033.25921645CS
156-0.625-15.43209876544.054.7251.6912305863.04423958CS
2601.845116.7721518991.5890.8821324773.71451678CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
CTNTCheetah Net Supply Chain Service Inc
US$ 5.35
(186.10%)
98.93M
ZJKZJK Industrial Company Ltd
US$ 11.925
(88.09%)
12.98M
CTORCitius Oncology Inc
US$ 1.70
(66.67%)
88.69M
GWAVGreenwave Technology Solutions Inc
US$ 0.584
(60.00%)
269.46M
JANXJanux Therapeutics Inc
US$ 63.112
(57.07%)
4.27M
REVBRevelation Biosciences Inc
US$ 0.593
(-37.57%)
2.44M
OMEXOdyssey Marine Exploration Inc
US$ 0.4752
(-36.23%)
2.88M
SNTISenti Biosciences Inc
US$ 6.865
(-31.35%)
5.37M
XCURExicure Inc
US$ 15.7384
(-29.42%)
288.02k
STSSSharps Technology Inc
US$ 2.37
(-29.33%)
149.31k
GWAVGreenwave Technology Solutions Inc
US$ 0.5828
(59.67%)
269.5M
SMCISuper Micro Computer Inc
US$ 41.10
(-2.14%)
139.94M
CTNTCheetah Net Supply Chain Service Inc
US$ 5.35
(186.10%)
98.93M
CHRSCoherus BioSciences Inc
US$ 2.04
(48.91%)
92.88M
CTORCitius Oncology Inc
US$ 1.70
(66.67%)
88.69M

ABUS Discussion

게시물 보기
db7 db7 3 주 전
nice new Blackrock 13F: https://stocktwits.com/bs010101/message/592459944
👍️0
db7 db7 3 주 전
2 days to AASLD...
👍️0
mick mick 1 월 전
👍️0
db7 db7 2 월 전
2 late breakers for AASLD: https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-announces-multiple-abstracts-highlighting-imdusiran-data
👍️0
mick mick 2 월 전
https://www.stockscores.com/charts/charts/?ticker=ABUS
👍️0
mick mick 3 월 전
ABUS
Arbutus Biopharma Corporation
4.5488
0.0388 (0.86%)
Volume: 1,579,948
Day Range: 4.39 - 4.56
Last Trade Time: 7:46:00 PM EDT
👍️0
db7 db7 3 월 전
breaking out; dare i say 'someone' knows 'something'(?)
👍️0
db7 db7 3 월 전
ARBUTUS PHARMA CORP. et al v. PFIZER INC. et al "Please take notice that an in-person Markman Hearing is hereby scheduled for 12/18/2024 at 10:30AM in Trenton- Courtroom 4W. So Ordered by Judge Zahid N. Quraishi on 9/3/2024. (kas)"
👍️0
db7 db7 3 월 전
ABUS over $4
👍️0
Monksdream Monksdream 3 월 전
ABUS under $4
👍️0
DewDiligence DewDiligence 4 월 전
ABUS pares pipeline–reduces workforce 40%:

https://finance.yahoo.com/news/arbutus-reports-second-quarter-2024-113000099.html

The company’s will focus on clinical development of Imdusiran regimens for HBV, but will terminate research on new HBV compounds.

Oddly (for the reason mentioned at the bottom of #msg-174556022), ABUS opted to retain its oral PD-1 program.
👍️0
Rockurstocks Rockurstocks 4 월 전
Not for long! $ABUS$
👍️0
Monksdream Monksdream 4 월 전
ABUS under $4
👍️0
mick mick 5 월 전
ABUS
Arbutus Biopharma Corporation
3.645
-0.135 (-3.57%)
Volume: 449,700
Day Range: 3.645 - 3.845
Last Trade Time: 2:29:04 PM EDT
👍️0
Monksdream Monksdream 5 월 전
ABUS new 52/week high
👍️0
db7 db7 5 월 전
👍️0
db7 db7 6 월 전
https://www.sec.gov/Archives/edgar/data/1447028/000089542124000390/ArbutusABUS.txt
👍️0
db7 db7 6 월 전
New Presentation: https://investor.arbutusbio.com/static-files/f33bde13-92b8-48c4-a40e-36cf6dd25852
👍️0
db7 db7 6 월 전
Poster for EASL https://www.arbutusbio.com/wp-content/uploads/2024/06/WED-371-Yuen-et-al-AB-729-201-IFN-poster-EASL-2024_FINAL.pdf
👍️0
mick mick 6 월 전
ABUS
Arbutus Biopharma Corporation
3.341
-0.019 (-0.57%)
Volume: 534,638
Day Range: 3.30 - 3.385
Last Trade Time: 12:14:00 PM EDT
Delayed by 15 minutes
👍️0
db7 db7 6 월 전
EASL June 6-8th:
https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-present-imdusiran-data-easl-congress-2024

"
HBsAg = LLOQ (lower limit of quantification) with detectable anti-HBs was observed at end-of-treatment in 28% of subjects who received 4 or 6 doses of imdusiran plus 24 weeks of IFN
"
👍️0
db7 db7 6 월 전
Arbutus is waking up a little following yesterday's Motion to Dismiss with Acuitas:
https://www.law360.com/ip/articles/1839088/judge-tosses-acuitas-covid-biotech-ip-suit-

other important events of late include:

1) company stating they have stopped their ATM and don't see a need to use it the rest of this year

2) the Markman order against Moderna that went in their favor:
https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-biopharma-announces-claim-construction-ruling-its

3) Activist becoming involved:
https://www.morningstar.com/news/business-wire/20240517970994/whitefort-capital-publishes-open-letter-to-arbutus-biopharma-shareholders-outlining-paths-to-maximize-value
👍️0
db7 db7 7 월 전
issue here, now, might be too many open $3 calls? will mm's hold her under....
👍️0
db7 db7 7 월 전
mgmt killed this stock with that ATM; imo, used in a suspicious manner... ie: they put a lid on her on the markman order release at $3ish .. WHY would you do that? They could have raised same money at double the price
👍️0
MWM MWM 7 월 전
Nice!
👍️0
db7 db7 7 월 전
https://www.businesswire.com/news/home/20240517970994/en/
👍️0
db7 db7 7 월 전
from Whitefort's 13D filed today: "The Reporting Persons have conveyed their view to the Issuer’s Board of Directors (the “Board”) that the current market price of the Shares does not reflect the Issuer’s intrinsic value. The Reporting Persons have requested that the Board immediately terminate the Issuer’s ATM program and explore all strategic options for the Issuer’s hepatitis B virus (HBV) portfolio. The Reporting Persons hope to continue to work constructively and collaboratively with the Board on these critical initiatives and intend to actively engage with shareholders and others regarding their views."
👍️0
Monksdream Monksdream 7 월 전
ABUS under $3
👍️0
mick mick 7 월 전
TWTR
Twitter Inc
53.70
0.00 (0.00%)
Volume:
👍️0
Monksdream Monksdream 8 월 전
ABUS new 52 hi
👍️0
db7 db7 8 월 전
looking a little better today; i guess it's going to be slow and steady and not the rocket on markman day like i hoped. i think this is looking really good med-long term on the litigation from after that markman ruling

also, looking forward to EASL in june
👍️0
mick mick 8 월 전
ABUS
Arbutus Biopharma Corporation
3.00
0.08 (2.74%)
Volume: 1,253,240
Day Range: 2.86 - 3.11
Bid: 2.99
Ask: 3.00
Last Trade Time: 9:56:51 AM EDT
Total Trades: 3,890
👍️0
mick mick 8 월 전
ABUS
Arbutus Biopharma Corporation
3.00
0.08 (2.74%)
Volume: 1,253,240
Day Range: 2.86 - 3.11
Bid: 2.99
Ask: 3.00
Last Trade Time: 9:56:51 AM EDT
Total Trades: 3,890
👍️0
mick mick 8 월 전
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
mick mick 8 월 전
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
mick mick 8 월 전
Arbutus to Participate in Two Upcoming Investor Conferences
03/08/2024 07:30:00 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
mick mick 8 월 전
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
04/04/2024 08:30:49 AM
Arbutus to Participate in Two Upcoming Investor Conferences
03/08/2024 07:30:00 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
Paullee Paullee 8 월 전
07:15 AM EDT, 04/04/2024 (MT Newswires) -- A US court ruled against Moderna (MRNA) in a patent infringement case by Arbutus (ABUS) over its COVID-19 vaccines, Reuters reported Wednesday.

US District Judge Mitchell Goldberg interpreted the patents in ways that favored Arbutus' case and hurt Moderna', Reuters reported.

Arbutus sued Moderna in 2022, claiming the company's COVID-19 vaccine impinged on its patents for lipid nanoparticles that shield the vaccine's mRNA from the body's immune system.

Moderna and Arbutus did not immediately respond to MT Newswires' requests for comment.
👍️0
MWM MWM 8 월 전
Watching all 3 stocks. $ABUS is kind of moving...
👍️0
db7 db7 8 월 전
was going to take all '3' to explode imo..
👍️0
MWM MWM 8 월 전
Yes, I'm trying to read it myself
👍️0
db7 db7 8 월 전
decision is out; looks like arbutus won '2' and moderna '1' .. please confirm
👍️0
db7 db7 9 월 전
https://dailycaller.com/2024/03/14/drew-johnson-moderna-covid-vax-patent-infringement-biden-admin/
👍️ 1
Desert dweller Desert dweller 9 월 전
My bad on post a few weeks ago. When I posted about $MRNA cash position, I didn't do the research I should have done and used what was on cash flow statement and didn't look into long term investments, very sloppy of me. Sorry about that.

In today's release, they are projecting to use $4.3 billion of their cash plus investments during 2024. At 12/31/23 they reported cash plus LT investments of $13.3 billion and project about $9 billion at end of 2024. It will take longer than I thought for them to run out of cash and hopefully $ABUS takes a huge chunk of it. Today MRNA had a surprise profit, and I am still hoping that $ABUS finally cleans their clock for their blatant theft of IP.
👍️ 1
Desert dweller Desert dweller 10 월 전
Handle on twitter is @DesertDweller93
👍️0
MWM MWM 10 월 전
Great post!

What’s your handle on Twitter?
👍️0
Desert dweller Desert dweller 10 월 전
I've been saying on X for a month or so that $MRNA will be suffering a drop once it becomes known that they have roughly a year's worth of cash left, I just discovered this recently. They are burning almost $7 billion/year and they will report less than that at 12/31/23. That on top of the fact that during the past 3 years, they spent $7 billion in buybacks at prices much higher than current prices, all the way up to $300+. My prediction is major restructuring or significant secondary very soon. I bet they wish they had that cash now instead of overpriced treasury stock but then mgt wouldn't have been able to sell at those inflated covid prices.

Hope $ABUS puts them into bankruptcy, the f'n thieves and I hope ABUS cleans $PFE and Biontech's clock too. They all know they are stealing the tech and just don't care. About time David kicks Goliath's ass again.
👍️0
MWM MWM 10 월 전
A couple bad headlines for MRNA of late. Here is one of todays...

Moderna’s RSV Vaccine May Lose Efficacy Faster Than GSK and Pfizer’s
👍️0
db7 db7 10 월 전
yes, quite the drop yesterday and today on mrna... g/l!
👍️0
MWM MWM 10 월 전
Puts on $MRNA might be the best play. If they have to pay up to $ABUS I have a feeling it might see a precipitous drop...

MRNA bad news is piling up there...
👍️0

최근 히스토리

NASDAQ
ABUS
Arbutus Biopharma
NASDAQ
WORX
SCWorx
LSE
ICP
Intermediate Capital
AQSE
TE10.GB
Test Stock 10
ASX
1ADO
AdAlta
EU
ORA
Orange
COIN
API3GBP
API3
COIN
AFINEUR
Asian Fintech
COIN
ARNXBTC
Aeron
COIN
APTETH
Aptos
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유